8-K: Vaxart Delisted from Nasdaq After Failed Split

Vaxart, Inc. announced its common stock will be delisted from Nasdaq after failing to meet listing conditions, including the withdrawal of a reverse stock split proposal.

Summary

• Vaxart, Inc. received a delisting notice from Nasdaq on September 19, 2025, confirming its securities will be removed from the exchange.
• The delisting stems from the company's noncompliance with conditions previously set by the Nasdaq Hearings Panel on August 27, 2025.
• Key conditions for continued listing included shareholder approval for a reverse stock split by September 5, 2025, and completion of the split by October 6, 2025, along with meeting the minimum bid price requirement.
• Vaxart withdrew its proposal to effect a reverse stock split on September 18, 2025, which directly led to the noncompliance.
• Trading of Vaxart's common stock on Nasdaq was already suspended as of July 8, 2025.
• The company's common stock is currently quoted on the OTCQX Best Market under the symbol VXRT.

Sentiment

Score: 2

Explanation: The confirmed delisting from Nasdaq to the OTCQX Best Market is a highly negative event, indicating a failure to meet fundamental listing requirements and likely leading to reduced liquidity and investor confidence.

Negatives

• Delisting of common stock from Nasdaq, a major U.S. stock exchange.
• Failure to satisfy Nasdaq's continued listing rules and conditions, including the minimum bid price requirement.
• Withdrawal of the reverse stock split proposal, which was a critical condition for maintaining Nasdaq listing.
• Trading on Nasdaq was suspended since July 8, 2025, indicating prior issues.
• Transfer of trading to the OTCQX Best Market, which typically offers lower liquidity and transparency compared to Nasdaq.

Risks

• Reduced liquidity and potentially wider bid-ask spreads for Vaxart's common stock on the OTCQX Best Market.
• Potential decrease in investor confidence and institutional interest due to delisting from a major exchange.
• Increased volatility in the stock price on the OTCQX market.
• Challenges in attracting new capital or maintaining the existing investor base.
• Difficulty in regaining a listing on a major exchange in the future.

Future Outlook

Vaxart's common stock will continue to be quoted on the OTCQX Best Market under the symbol VXRT following its delisting from Nasdaq.

Industry Context

Delisting from a major exchange like Nasdaq to the OTCQX Best Market is a significant negative event for any publicly traded company, often signaling financial distress or a failure to meet regulatory standards. It typically results in reduced visibility, liquidity, and investor confidence, making it harder for the company to raise capital or attract institutional investors. For biotechnology companies like Vaxart, maintaining a strong public market presence is crucial for funding research and development and attracting partnerships.

Stakeholder Impact

• Shareholders will likely experience reduced liquidity, potentially wider bid-ask spreads, and decreased visibility for their shares, which could negatively impact share price and ease of trading.
• Investors may face challenges in valuing the company and reduced institutional interest due to trading on the OTCQX market.
• Company management will need to navigate the implications of trading on a less prominent market and address investor concerns regarding the company's future.

Next Steps

• Vaxart's common stock will continue to be quoted on the OTCQX Best Market under the symbol VXRT.

Key Dates

Recommendation

The confirmed delisting from Nasdaq to the OTCQX Best Market is a significant negative event. It implies a failure to meet fundamental listing requirements, which often leads to reduced liquidity, decreased investor confidence, and potential further share price depreciation. Trading on the OTCQX typically results in less transparency and institutional interest. For a seasoned investor, this development signals increased risk and a likely deterioration of investment fundamentals, warranting a 'sell' recommendation to mitigate further losses or reallocate capital to more stable opportunities.

Keywords

Vaxart, VXRT, Nasdaq, Delisting, Reverse Stock Split, OTCQX, Biotechnology, SEC Filing, 8-K